DNA-Caryometry

What we do

AI-Assisted, low-impact cancer diagnostics

  • Non invasive – Samples can be obtained through brush biopsy, body fluids, or fine needle aspirations

  • AI assisted – Swift computer analysis of cell-nuclei speeds up the workflow, doctors can focus on final confirmation

  • Early diagnosis – DNA-Cytomety / -karyometry can detect cancers up to 2 years earlier than histopathological methods

Diagnostic DNA-Caryometry

A combination of AI-based diagnostic classification of nuclear images and the assessment of DNA-aneuploidy as indicator of malignancy.

  • Specimen samples – are taken usually by brush biopsy, body fluids, or fine needle aspirations

  • Preparation – Specimens are then prepared to be placed on a glass-slide for microscopical analysis.

  • Segmentation – the process the AI goes through to individually identify each nucleus.

  • Image processing – Glare-, shading- and diffraction correction.

  • Classification – Once segmented the AI needs to determine what type of cell each segmented cell is.

  • Measurements – Once the appropriate nuclei are selected and classified, different measurements are performed. 17 different morphometric parameters are used for assessment.

  • Analysis – Nuclei are classified into different types and as being suspicious for malignancy (abnormals). In a second step their DNA-content is determined. DNA-aneuploidy is used as a specific marker of cancer cells.

  • Documentation – the computer will finally present the numerical results of measurements, graphs of their distribution and an image-gallery of nuclei for closer inspection.

  • Cytometric result – Check of data and classifications by professional (cyto-) pathologist.

Prostate cancer prognosis

DNA-Cytometry can provide important additional information for the prediction of individual prostate tumour progression and can assisst in developing an appropriate treatment plan. DNA-cytometry is an accurate method for the grading of malignancy, especially for prostate tumours. The content of the DNA is measured in hundreds of cancer-nuclei. The increase of DNA-matter per nucleus and their variation provide an objective and more accurate and insight into tumour malignancy than the Gleason-Score. DNA-Cytometry can help patients with a clinically insignificant low-stage carcinoma base their decision for or against an active surveillance strategy on a scientific foundation.

The Founders

Prof. Alfred Boecking
Prof. Alfred Boecking
Prof. Böcking was Head of Cytopathology at the University Hospital of Düsseldorf from 1994 to 2009. He also held the position of President of the European Society for Analytical Cellular Pathology from 1995 to 1998. He is one of the key pioneers in Cytopathology and Image based Cytometry. Today Prof. Böcking is CTO of Objective Diagnostics Systems Inc.
Dr. Branko Palcic
Dr. Branko Palcic
Dr. Branko Palcic was the founder and Head of BC Cancer’s Cancer Imaging Department from 1995 to 2001. He is a key pioneer in Image based Cythometry cancer screening. He served as Director of Technology Development for BC Cancer Agency until 2002. Today Dr. Branko is Co- founder and CEO of Objective Diagnostic Systems Inc.